July 10, 2025

Genetic Traits Influence Children’s Food Preferences

A new study presented at the ADA’s 85th Scientific Sessions links genetic predisposition for macronutrient preference with childhood intake of sugary drinks and fast food.

Conexiant

July 09, 2025

Once-Weekly Combo Injection Cuts Weight by 20% 

A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.

Conexiant

July 08, 2025

Orforglipron Lowers A1c, Weight in T2D Patients 

A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.

Conexiant

July 08, 2025

Weekly Efsitora Matches Glargine in HbA1c Control

The regimen also showed lower hypoglycemia rates in insulin-naive adults with type 2 diabetes.

Conexiant

July 07, 2025

Cagrilintide–Semaglutide Yields Weight, A1c Gains

Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.

Conexiant

July 01, 2025

Stem Cell Therapy Shows T1D Reversal Potential

A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

CGM Boosts Wound Healing, Lowers A1c: Study

Short-term CGM use improved A1c, wound healing, and reduced ED visits in diabetic foot patients, per data from ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant